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Background/Aims: Nonalcoholic fatty liver disease (NAFLD) has recently been found to be a novel component of metabolic 
syndrome (MS), which is one of the leading causes of chronic liver disease. The serum alanine aminotransferase (ALT) and γ
-glutamyltransferase (GGT) levels are suggested to affect liver fat accumulation and insulin resistance. We assessed the 
associations of serum ALT and GGT concentrations within the reference ranges with MS and NAFLD. Methods: In total, 1,069 
subjects enrolled at the health promotion center of Wonkwang University Hospital were divided into 4 groups according to serum 
ALT and GGT concentrations levels within the reference ranges. We performed biochemical tests, including liver function tests 
and lipid profiles, and diagnosed fatty liver by ultrasonography. Associations of ALT and GGT concentrationgrading within the 
reference range with fatty liver and/or MS were investigated. Results: The presence of MS, its components, and the number of 
metabolic abnormalities [except for high-density lipoprotein-cholesterol (HDL-C) and fasting blood glucose] increased with the 
ALT level, while the presence of MS, its components, and the number of metabolic abnormalities (except for HDL-C) increased 
with the GGT level. The odds ratios for fatty liver and MS increased with the ALT level (P<0.001 and P=0.049, respectively) and 
the GGT level (P=0.044 and P=0.039, respectively). Conclusions: Serum ALT and GGT concentrations within the reference 
ranges correlated with the incidence of NAFLD and MS in a dose-dependent manner. There associations need to be confirmed 
in large, prospective studies. (Korean J Hepatol 2011;17:27-36)
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common 
liver disorder in Western countries, affecting 20-30% of the 
general population.
1,2 The prevalence of NAFLD has increased 
substantially during the last 15 years in parallel with regional 
trends in over-nutrition central and overall obesity, type 2 
diabetes mellitus (DM), and the metabolic syndrome (MS).
3-5
NAFLD, characterized by elevated alanine aminotransferase 
(ALT) and γ-glutamyltransferase (GGT), is now considered as 
the hepatic expression of insulin resistance (IR),
6 accounting for 
the risk of advanced liver disease observed in these patients, in 
addition to the well-established risk of cardiovascular disease. 
Serum ALT is associated with liver fat accumulation as a 28  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011 
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Figure 1. Study profile. 
HBV, hepatitis B virus; HCV, hepatitis C virus; LC, liver 
cirrhosis; Abnormal ALT, abnormal alanine aminotransferase; 
GGT level, gamma glutamyltransferase level. 
marker of hepatic steatosis or hepatic dysfunction. Also, as a 
gluconeogenic enzyme, the ALT is associated with hepatic IR.
7 
A number of MS components, obesity, IR, and high sensitivity- 
C-reactive protein (hs-CRP), are strong predictors of increased 
ALT activity in NAFLD.
8 Elevated serum ALT levels have a 
positive association with MS-related diseases, such as type 2 DM 
and cardiovascular disease.
9,10
In recent data, both normal and increased levels of ALT are 
associated with long-term development of multiple metabolic 
disorders. These results indicate the potential for ALT values 
within the reference interval as biomarkers for the risk of MS.
11 
Several prospective epidemiologic studies have demonstrated 
that increased concentrations of hepatic enzyme in serum, even 
within the reference interval, may be related to an increased risk 
of type 2 DM and the MS, as well as death.
12 In addition, ALT is 
a predictor of mortality due to unrecognized liver diseases, but 
also due to other causes of ALT elevation, linked to non-liver 
health risks, such as atherosclerosis, hypertension (HTN), and 
type 2 DM.
7 Even within the normal range, there is a positive 
association between the aminotransferase concentration and 
mortality from liver disease.
13
As GGT is a sensitive indicator of liver damage,
14 excess 
deposition of fat in the liver is associated with an elevated serum 
GGT and IR.
15,16 GGT is located on the external surface of most 
cells and mediates the uptake of glutathione,
17 an important 
component of intracellular oxidative defenses.
18 GGT is also 
considered a marker of oxidative stress and it may be directly 
involved in the generation of reactive oxygen species. The serum 
GGT level has been associated with many cardiovascular disease 
risk factors, DM, MS, and IR.
18,19 In Korean adults, serum GGT 
is closely correlated with IR and the increased number of 
components of MS,
20 as a surrogate marker of IR, inflammation, 
and MS.
21 Some studies suggest that within its reference interval, 
the serum GGT concentration has been closely related to the 
presence of components of the MS.
7 Recent reports suggest that 
an increased GGT level is a risk factor for advanced fibrosis in 
NAFLD
21 and, with weight loss, a decrease in GGT activity is 
predictive of improved lobular inflammation and fibrosis of 
liver.
20
Thus, measurement of ALT and GGT may identify subjects in 
the general population with a risk of NAFLD and MS.
7 However, 
limited data exist on the significance of GGT or ALT activities 
within reference interval in subjects with NAFLD and MS. 
Therefore, we assessed the association of serum ALT and GGT 
activities within reference range with MS and NAFLD.
MATERIALS AND METHODS
Subjects 
The medical records of 2,024 subjects who attended our 
Center for Health Promotion for a medical check-up between 
2006 and 2008 were investigated. Subjects meeting any of the 
following criteria were excluded: hepatic enzyme/GGT con-
centrations higher than the upper limit of the reference range, a 
positive test for hepatitis C virus antibody, a positive test for 
hepatitis B virus surface antigen, a daily alcohol intake of 20 g or 
more, liver cirrhosis, or incomplete data for determination of the 
MS (Fig. 1). 
The subjects were classified separately into four groups 
according to the serum ALT and GGT activities within reference 
range, as in previous report.
18 According to ALT and GGT 
activities, subjects were divided into four group respectively 
as below; ALT grading (first 1-14 IU/L, second 15-19 IU/L, third 
20-25 IU/L, and fourth 26-40 IU/L); GGT grading (first 1-10 
IU/L, second 11-15 IU/L, third 16-24 IU/L, and fourth 25-50 
IU/L). Considering sexual difference, group of ALT activity was 
divided into male and female groups.
Assessment of hepatic steatosis
We used ultrasonography as a non-invasive method to diag-
nose fatty liver disease. All ultrasound scans were performed by 
two skilled operators using a high resolution B-mode scanner 
(SSD-5500; Aloka, Tokyo, Japan). Liver steatosis was assessed 
on the basis of abnormally intense, high-level echoes arising 
from the hepatic parenchyma, the liver-kidney difference in echo 
amplitude, the echo penetration into the deep portion of the liver, 
and the clarity of the blood vessel structure in the liver.
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Table 1. Baseline characteristics of the male subjects according to serum alanine aminotransferase (ALT) grading 
ALT grading (IU/L), numbers, %
P-value
*
First (1-14)
n=39, 8.1%
Second (15-19)
n=137, 28.5%
Third (20-25)
n=159, 33.1%
Fourth (26-40)
n=145, 30.2%
Total
n=480
Age (years) 44.7±10.6 43.5±8.8 47.2±8.9 46.1±10.3 45.6±9.5 0.047
Body weight (kg) 63.0±6.7 64.7±8.2 66.6±8.3 69.7±8.4 66.7±8.5 0.000
BMI (kg/m
2) 21.8±2.0 22.9±2.4 23.7±2.8 24.7±2.8 23.6±2.8 0.000
BMI>25 (n, %) 3 (7.7%) 31 (22.6%) 46 (28.9%) 65 (44.8%) 145 (30.2%) 0.000
WC (cm) 74.2±7.3 77.2±7.8 80.6±8.1 82.2±8.3 81.4±7.4 0.000
Sys. BP (mmHg) 120 (110-130) 119.6 (110.7-129.4) 120 (110-130) 130 (120-140) 120 (110-130) 0.000
Dia. BP (mmHg) 70 (70-80) 79.1 (75.1-83.1) 70 (70-80) 80 (70-80) 70 (70-80) 0.000
Cigarettes smoke/week (packs) 0.0 (0-14.7) 0.0 (0-14.79) 0.5 (0-12.2) 1.9 (0-8.3) 0.0 (0-15) 0.036
WBC (/μL) 6.34 (5.5-7.3) 6.28 (5.3-7.3) 6.3 (5.2-7.5) 6.2 (5.4-7.1) 6.3 (5.3-7.4) 0.833
Hb (g/dL) 14.6 (14.0-15.4) 14.9 (14.4-15.6) 15.0 (14.5-15.7) 15.2 (14.4-15.8) 15 (14.4-15.7) 0.003
Glucose (mg/dL) 89 (82.1-92.8) 88 (79.4-94.3) 88 (80.8-95.8) 89 (79.8-96.9) 88 (80.5-95.5) 0.484
Uric acid (mg/dL) 5.4±1.0 5.3±1.1 5.5±1.1 5.8±1.2 5.5±1.1 0.002
T-bil. (mg/dL) 1.0 (0.8-1.3) 1.1 (0.9-1.4) 1.1 (0.8-1.4) 1.1 (0.9-1.4) 1.1 (0.9-1.4) 0.726
AST (IU/L) 16 (14.5-18.1) 19 (17.2-21.7) 20 (18.5-28.2) 24 (21.2-27.6) 21 (18-24) 0.000
GGT (IU/L) 18 (15.8-25) 23 (18.4-29.6) 28 (21.4-35.5) 32.3 (27.8-39.5) 26 (20-34) 0.000
Cr (mg/dL) 1.1 (1.0-1.2) 1.0 (0.9-1.1) 1.0 (1.0-1.1) 1.0 (1.0-1.1) 1 (1.0-3.4) 0.308
T-chol. (mg/dL) 177.0±27.3 189.0±29.1 188.2±27.3 193.0±35.5 189.0±30.7 0.018
HDL-C (mg/dL) 48 (43.4-52.9) 51 (44.8-59.8) 47 (41.2-54.6) 47.9 (41.5-54.1) 48 (42-56) 0.042
TG (mg/dL) 84 (76.2-119.3) 91 (66.5-123) 99 (65-149.5) 112 (76-158.5) 98.5 (68-143) 0.004
LDL-C. (mg/dL) 111.4±24.0 119.1±27.7 119.6±27.1 123.1±34.3 119.8+/-29.5 0.104
T-chol.>200 mg/dL (n, %) 8 (20.5%) 47 (34.3%) 56 (35.2%) 63 (43.4%) 174 (36.3%) 0.052
LDL-C.>130 mg/dL (n, %) 11 (28.2%) 50 (36.5%) 61 (38.4%) 60 (41.4%) 182 (37.9%) 0.488
Data are expressed as means±SD, medians (interquartile ranges) for skewed variables, or proportions for categorical variables. 
Differences were assessed using the Kruskal-Wallis H test for continuous variables or the chi-square tests for categorical variables.
* Tested by the Spearman’s rank correlation analysis.
WC, waist circumference; Sys. BP, systolic blood pressure; Dia. BP, diastolic blood pressure; T-bil., total bilirubin; AST, aspartate 
aminotransferese; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; Cr, creatinine; T-chol., total cholesterol; LDL-C., 
LDL cholesterol; TG, triglyceride; HDL-C., HDL-cholesterol.
Definition of MS
According to the International Diabetes Federation (IDF) 
consensus statement, MS was defined as the presence of 3 or 
more of the followings: i) waist circumference (WC) ≥90 cm in 
men and ≥80 cm in women; ii) serum triglyceride (TG) ≥150 
mg/dL; iii) high-density lipoprotein cholesterol (HDL-C) <50 
mg/dL in females and <40 mg/dL in men; iv) systolic blood 
pressure (BP) ≥ 130 or diastolic BP ≥85 mmHg or treatment of 
previously diagnosed HTN; v) fasting blood glucose ≥100 
mg/dL or treated type 2 DM.
23
Subject assessment and anthropometric 
measurements
A self-administered questionnaire also served to measure 
medical history of the examinee and family, medication 
history, and lifestyle (cigarette smoking, drinking alcohol, 
and exercise). Anthropometric measurements of height, 
body weight, and WC were made on the same day. The 
height was measured to the nearest 0.5 cm. The body weight 
was measured in light clothing and without shoes to the 
nearest 0.1 kg. The WC was measured to the nearest 0.1 cm 
with flexible tape at the midpoint between the lower rib 
margin and the iliac crest in the horizontal position. 30  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011 
Table 2. Baseline characteristics of the female subjects according to serum ALT grading
ALT grading (IU/L), numbers, %
P-value
*
First (1-14)
n=197, 37.5%
Second (15-19)
n=157, 29.9%
Third (20-25)
n=100, 19%
Fourth (26-40)
n=71, 13.5%
Total
n=523
Age (years) 39.2±9.2 46.8±10.8 48.5±10.5 49.1±10.2 44.6±10.9 0.000
Body weight (kg) 54.5±6.9 55.0±7.8 57.7±8.5 57.5±8.8 55.6±7.8 0.001
BMI (kg/m
2) 22.0±2.7 22.6±2.8 23.6±3.2 24.1±3.4 22.8±3.0 0.000
BMI >25 (n, %) 26 (13.2%) 27 (17.2%) 29 (29%) 20 (28.2%) 102 (19.4%) 0.002
WC (cm) 73.6±7.6 75.5±8.1 78.2±8.9 78.7±8.5 75.7±8.3 0.000
Sys. BP (mmHg) 110 (100-120) 110 (110-122.5) 120 (110-130) 130 (110-140) 120 (110-130) 0.000
Dia. BP (mmHg) 70 (60-80) 70 (60-80) 70 (60-80) 70 (70-80) 70 (60-80) 0.003
Cigarettes smoke/week (packs) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.500
WBC (/μL) 6.1 (4.9-7.0) 5.9 (4.9-6.9) 5.7 (5-7.1) 5.7 (4.9-7.3) 5.7 (4.9-6.9) 0.969
Hb (g/dL) 12.6 (11.9-13.1) 12.7 (12.1-13.3) 13.2 (12.3-13.6) 13.2 (12.3-13.9) 12.9 (12.2-13.5) 0.000
Glucose (mg/dL) 85 (78-92) 86 (79-91) 86 (81.25-94) 88 (80-96) 86 (80-92) 0.019
Uric acid (mg/dL) 3.9±0.8 3.9±0.9 4.1±1.0 4.4±1.1 4.0±0.9 0.000
T- bil. (mg/dL) 0.8 (0.6-1.0) 0.8 (0.6-1.1) 0.8 (0.7-1.0) 0.8 (0.6-1.0) 0.8 (0.6-1.0) 0.987
AST (IU/L) 15.5 (14-17) 17 (15-19) 21 (18-24) 25 (22-28) 18 (16-22) 0.000
GGT (IU/L) 13 (11-16) 14 (12-18) 17 (14-23) 23 (18-28) 16 (12-21) 0.000
Cr (mg/dL) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.845
T-chol. (mg/dL) 178.8±29.3 192.0±32.5 196.3±35.4 197.4±34.1 188.6±33.0 0.000
HDL-C. (mg/dL) 58 (48-65) 57 (47.75-65) 53 (45-59) 54 (44-60) 56 (46-64) 0.005
TG (mg/dL) 76 (56.5-95.5) 78 (57-107) 98.5 (66.3-132) 73.46 (64-137) 82 (59-114) 0.000
LDL-C. (mg/dL) 107.7±25.0 116.8±28.6 120.3±29.8 122.6±28.6 114.9±28.1 0.000
T-chol. >200 mg/dL (n, %) 55 (23.3%) 106 (36.1%) 95 (36.7%) 93 (43.1%) 349 (34.7%) 0.004
LDL-C. >130 mg/dL (n, %) 50 (21.2%) 95 (32.3%) 96 (37.1%) 86 (39.8%) 327 (32.5%) 0.008
Data are expressed as means±SD, medians (interquartile ranges) for skewed variables, or proportions for categorical variables. 
Differences were assessed using the Kruskal-Wallis H test for continuous variables or the chi-square tests for categorical variables. 
* Tested by the Spearman’s rank correlation analysis.
WC, waist circumference; Sys. BP, systolic blood pressure; Dia. BP, diastolic blood pressure; T-bil., total bilirubin; AST, aspartate 
aminotransferese; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; Cr, creatinine; T-chol., total cholesterol; LDL-C., 
LDL cholesterol; TG, triglyceride; HDL-C., HDL-cholesterol.
Biochemical and metabolic measurements
After an overnight fast, subjects underwent liver function 
tests [aspartate aminotransferase (AST), ALT, GGT, alkaline 
phsophatase, albumin, and total bilirubin], lipid profiles [total 
cholesterol (TC), TG, HDL-C, and low-density lipoprotein 
cholesterol (LDL-C)], glucose, creatinine, and hemoglobin (Hb).
Statistical analysis 
Statistical analysis was performed by the Statistical Package 
for Social Science (SPSS), version 17.0 (SPSS, Inc., Chicago, 
IL, USA). Results are expressed as the means±standard 
deviations or median (interquartile range) for continuous 
variables and as frequencies (proportions) for categorical 
variables. The trends for each variables with increasing 
ALT/GGT gradings were evaluated by the Spearman’s rank 
correlation analysis. Continuous variables were compared 
using the Kruskal-Wallis H test. Categorical parameters 
among groups were compared using the chi-square test. The 
factors (ALT grading and GGT grading) correlated with 
fatty liver or metabolic syndrome were evaluated using 
multiple logistic regression analysis after adjustment for 
clinical and biochemical parameters. Using ROC, levels of 
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Table 3. Baseline characteristics of all of the study subjects according to serum γ-glutamyltransferase (GGT) grading
GGT grading (IU/L), numbers, %
P-value
*
First (1-10)
n=63, 6.3%
Second (11-15)
n=230, 22.9%
Third (16-24)
n=358, 35.6%
Fourth (25-50)
n=354, 35.2%
Total
n=1005
Age (years) 40.2±9.4 42.9±10.9 45.2±9.7 47.3±10.0 45.1±10.3 0.473
Male (n,%) 4 (6.3%) 29 (12.6%) 179 (50.0%) 268 (75.7%) 480 (47.8%) 0.000
BW (kg) 54.1±6.4 56.5±8.5 60.2±9.5 65.7±9.3 60.92±9.85 0.000
BMI (kg/m
2) 21.7±2.1 22.5±2.8 22.8±2.8 24.3±2.9 23.19±2.92 0.002
BMI>25 kg/m
2 (n, %) 3 (4.8%) 40 (17.4%) 68 (19%) 136 (38.4%) 247 (24.6%) 0.124
WC (cm) 72.2±6.6 75.5±7.8 77.8±8.4 82.2±7.4 78.5±8.4 0.000
Sys. BP (mmHg) 110 (100-120) 120 (100-130) 120 (110-130) 120 (110-140) 120 (110-130) 0.541
Dia.BP (mmHg) 70 (60-70) 70 (60-80) 70 (60-80) 70 (70-80) 70 (60-80) 0.346
Cigarettes smoke/wk (packs) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.313
WBC (/ul) 5.4 (4.4-6.3) 5.7 (4.8-7.1) 5.9 (5.1-7.1) 6.4 (5.2-7.5) 6.0 (5.0-7.1) 0.178
Hb (g/dL) 12.2 (11.5-13.2) 12.9 (12.2-13.5) 13.9 (12.9-14.9) 14.9 (13.9-15.6) 13.8 (12.7-15) 0.000
Glucose (mg/dL) 86 (82-90) 86 (80-90) 86 (78.8-94) 89 (81.8-97) 87 (80-94) 0.797
Uric acid (mg/dL) 3.77±0.67 4.06±0.92 4.73±1.23 5.32±1.29 4.73±1.27 0.000
T-bil. (mg/dL) 0.8 (0.7-1.0) 0.9 (0.7-1.1) 0.9 (0.7-1.3) 1.0 (0.8-1.3) 0.9 (0.7-1.2) 0.203
AST (IU/L) 18 (15-20) 17 (15-20) 19 (17-23) 22 (18.8-25) 19 (17-23) 0.000
ALT (IU/L) 14 (10-18) 15 (12-19) 19 (16-24) 23 (19-30) 19 (15-25) 0.000
Cr 0.8 (0.8-0.9) 0.8 (0.8-0.9) 0.9 (0.8-1.0) 1.0 (0.9-1.1) 0.9 (0.8-1) 0.001
T-chol. (mg/dL) 172.3±25.0 182.7±28.7 188.8±31.2 195.7±33.9 188.8±31.9 0.504
HDL-C. (mg/dL) 55 (43-65) 55 (45-64) 52.5 (44-66.3) 49 (42-56.3) 52 (44-60) 0.484
TG (mg/dL) 78 (51-94) 74 (55-102) 91 (66-121) 106 (75-159.3) 90 (63-129) 0.018
LDL-C. (mg/dL) 103.2±21.7 111.6±25.3 117.1±27.6 123.5±31.6 117.2±28.9 0.436
T-chol. >200 mg/dL (n, %) 8 (12.7%) 60 (26.1%) 124 (34.6%) 157 (44.4%) 349 (34.7%) 0.754
LDL-C. >130 mg/dL (n, %) 7 (11.1%) 54 (23.5%) 117 (32.7%) 149 (42.1%) 327 (32.5%) 0.610
Data are expressed as means±SD, medians (interquartile ranges) for skewed variables, or proportions for categorical variables. 
Differences were assessed using the Kruskal-Wallis H test for continuous variables or the chi-square tests for categorical variables. 
* Tested by the Spearman’s rank correlation analysis.
WC, waist circumference; Sys. BP, systolic blood pressure; Dia. BP, diastolic blood pressure; T-bil., total bilirubin; AST, aspartate 
aminotransferese; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; Cr, creatinine; T-chol., total cholesterol; LDL-C., 
LDL cholesterol; TG, triglyceride; HDL-C., HDL-cholesterol.
NAFLD and MS were evaluated. Statistical significance was 
considered to be a P<0.05. 
RESULTS
Prevalence of fatty liver by ultrasonography 
and MS
The 1,005 subjects [mean age, 45.08±10.26 years; 45.62±9.49 
(men); 44.59±10.90 (women)] of total 2,024 subjects were 
enrolled in this study. Among the men and women examined, 
ultrasonographic scans revealed fatty liver in 25.3% (254/1005); 
150/480 (men), 104/525 (women). Among the subjects exam-
ined, the prevalence of MS was 10.8% (109/1005); 53/480 
(men), 56/525 (women). Among 254 subjects with fatty liver by 
ultrasonography, 67 subjects (26.4%) had MS and, among 109 
subjects with MS, 67 subjects (61.5%) revealed fatty liver by 
ultrasonography.
Clinical and metabolic characteristics according 
to ALT and GGT activities
Clinical characteristics of the study subjects according to 
serum GGT and ALT were presented in Tables 1, 2 and 3. As 32  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011 
Table 4. Components of metabolic syndrome (MS), fatty liver, and severity of fatty liver according to serum ALT grading in male 
subjects
ALT grading (IU/L), numbers, %
P-value
*
First (1-14)
n=39, 8.1%
Second (15-19)
n=137, 28.5%
Third (20-25)
n=159, 33.1%
Fourth (26-40)
n=145, 30.2%
Total
n=480
Components of MS 1 (0-1) 0 (0-1.4) 1.1 (0.3-2.0) 1.4 (0.6-2.3) 0 (0-0) 0.000
Metabolic syndrome 2 (5.1%) 8 (5.8%) 21 (13.2%) 22 (15.2%) 53 (11.4%) 0.006
Systolic BP>130 mmHg 12 (30.8%) 44 (32.1%) 75 (47.2%) 84 (57.9%) 215 (44.8%) 0.000
Diastolic BP>85 mmHg 1 (2.6%) 10 (7.3%) 14 (8.8%) 30 (20.7%) 55 (11.5%) 0.000
TG >150 mg/dL 8 (20.5%) 20 (14.6%) 40 (25.2%) 43 (29.7%) 111 (23.1%) 0.005
HDL-C <40 mg/dL (m) <50 mg/dL (f) 6 (15.4%) 15 (10.9%) 28 (17.6%) 28 (19.3%) 77 (16.0%) 0.252
FBS >100 mg/dL 6 (15.4%) 15 (10.9%) 31 (19.5%) 27 (18.6%) 79 (16.5%) 0.202
WC >80 cm (f) >90 cm (m) 0 (0%) 8 (5.8%) 23 (14.5%) 30 (20.7%) 61 (12.7%) 0.000
TG >150 mg/dL 8 (20.5%) 20 (14.6%) 40 (25.2%) 43 (29.7%) 111 (23.1%) 0.008
Fatty liver 8 (20.5%) 24 (17.5%) 43 (27%) 75 (51.7%) 150 (31.3%) 0.000
Data are expressed as medians (interquartile ranges) for skewed variables, or proportions for categorical variables. Differences were 
assessed using the Kruskal-Wallis H test for continuous variables or the chi-square tests for categorical variables. 
* Tested by the Spearman’s rank correlation analysis.
MS, metabolic syndrome; WC, waist circumference; TG, triglyceride; FBS, fasting blood glucose; HDL-C, HDL cholesterol.
Table 5. Components of MS, fatty liver, and severity of fatty liver according to serum ALT grading in female subjects
ALT grading (IU/L), numbers, %
P-value
* 
First (1-14)
n=197, 37.5%
Second (15-19)
n=157, 29.9%
Third (20-25)
n=100, 19%
Fourth (26-40)
n=71, 13.5%
Total
n=523
Components of MS 1 (0-1) 1 (0-1) 1 (0-2) 1 (0-2) 1 (0-1) 0.000
Metabolic syndrome 6 (3%) 18 (11.5%) 16 (16%) 16 (22.5%) 56 (10.7%) 0.000
Systolic BP >130 mmHg 40 (20.3%) 48 (30.6%) 36 (36%) 37 (52.1%) 161 (30.7%) 0.000
Diastolic BP >85 mmHg 11 (5.6%) 16 (10.2%) 10 (10%) 14 (19.7%) 51 (9.7%) 0.007
TG >150 mg/dL 7 (3.6%) 25 (15.9%) 18 (18%) 14 (19.7%) 64 (12.2%) 0.000
HDL-C <40 mg/dL (m) <50 mg/dL (f) 55 (27.9%) 48 (30.6%) 38 (38%) 28 (38%) 168 (32%) 0.044
FBS >100 mg/dL 13 (6.6%) 15 (9.6%) 15 (15%) 11 (15.5%) 54 (10.3%) 0.008
WC >80 cm (f) >90 cm (m) 16 (8.1%) 19 (12.1%) 19 (19%) 16 (22.5%) 70 (13.3%) 0.000
TG >150 mg/dL 7 (3.6%) 25 (15.9%) 18 (18%) 14 (19.7%) 64 (12.2%) 0.000
Fatty liver 26 (13.2%) 21 (13.4%) 29 (29%) 28 (39.4%) 104 (19.8%) 0.000
Data are expressed as medians (interquartile ranges) for skewed variables, or proportions for categorical variables. Differences were 
assessed using the Kruskal-Wallis H test for continuous variables or the chi-square tests for categorical variables. 
* Tested by the Spearman’s rank correlation analysis.
MS, metabolic syndrome; WC, waist circumference; TG, triglyceride; FBS, fasting blood glucose; HDL-C, HDL cholesterol.
the ALT levels increased in male subjects, age, body weight 
(BW), BMI (body mass index), obesity (BMI>25), WC, 
systolic BP, diastolic BP, Hb, uric acid, AST, ALT, TG, and 
TC increased and HDL-C decreased (Table 1). As the ALT 
levels increased in female subjects, age, BW, BMI, obesity 
(BMI>25), WC, systolic BP, diastolic BP, Hb, fasting plasma 
glucose, uric acid, AST, ALT, TG, TC, TC (>200 mg/dL), 
and LDL-C (>130 mg/dL) increased and HDL-C decreased 
(Table 2). As the GGT levels increased in total subjects, age, 
BW, BMI, obesity (BMI>25), WC, systolic BP, diastolic BP, 
Hb, fasting plasma glucose, uric acid, AST, ALT, TG, TC, 
TC (>200 mg/dL), and LDL-C (>130 mg/dL) increased and 
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Table 6. Components of MS, fatty liver, and severity of fatty liver according to serum GGT grading in all of the subjects
GGT grading (IU/L), numbers
P-value
*
First (1-10)
n=63, 6.3%
Second (11-15)
n=230, 22.9%
Third (16-24)
n=358, 35.6%
Fourth (25-50)
n=354, 35.2%
Total
n=1005
Components of MS 1 (0-1) 1 (0-1) 1 (0-2) 1 (0-2) 1 (0-2) 0.000
Metabolic syndrome 3 (4.8%) 12 (5.2%) 35 (9.8%) 59 (16.7%) 109 (10.8%) 0.000
Systolic BP>130 mmHg 8 (12.7%) 58 (25.2%) 139 (38.8%) 171 (48.3%) 376 (37.4%) 0.000
Diastolic BP>85 mmHg 2 (3.2%) 17 (7.4%) 36 (10.1%) 51 (14.4%) 106 (10.5%) 0.001
TG>150 mg/dL 2 (3.2%) 18 (7.8%) 55 (15.4%) 100 (28.2%) 175 (17.4%) 0.000
HDL-C<40 mg/dL (m) <50 mg/dL (f) 20 (31.7%) 64 (27.8%) 82 (22.9%) 79 (22.3%) 245 (24.4%) 0.063
FBS>100 mg/dL 1 (1.6%) 14 (6.1%) 51 (14.2%) 67 (18.9%) 133 (13.2%) 0.000
WC>80 cm (f) >90 cm (m) 3 (4.8%) 19 (8.3%) 39 (10.9%) 70 (19.8%) 131 (13%) 0.000
TG>150 mg/dL 2 (3.2%) 18 (7.8%) 55 (15.4%) 100 (28.2%) 175 (17.4%) 0.000
Fatty liver 10 (15.9%) 35 (15.2%) 81 (22.6%) 128 (36.2%) 254 (25.3%) 0.000
Data are expressed as medians (interquartile ranges) for skewed variables, or proportions for categorical variables. Differences were 
assessed using the Kruskal-Wallis H test for continuous variables or the chi-square tests for categorical variables. 
* Tested by the Spearman’s rank correlation analysis.
MS, metabolic syndrome; WC, waist circumference; TG, triglyceride; FBS, fasting blood glucose; HDL-C, HDL cholesterol.
Table 7. Odds ratio and 95% confidence interval (CI) values for fatty liver and MS according to the baseline serum GGT and ALT gradings
Fatty liver P-value Metabolic syndrome
‡ P-value
ALT 2 (Ref;1) 0.812
* (.474-1.390) 0.000 2.651
§ (1.009-6.965) 0.049
     3 (Ref;1) 1.426
* (.838-2.424) 3.276
§ (1.250-8.587)
     4 (Ref;1) 3.126
* (1.800-5.429) 3.154
§ (1.500-11.067)
GGT 2 (Ref;1)  0.647
† (.286-1.461) 0.044 0.613
∥ (.123-3.072) 0.039
     3 (Ref;1)  1.037
† (.480-2.230) 1.817
∥ (.402-8.218)
     4 (Ref;1) 1.290
† (.596-2.790) 2.565
∥ (.541-12.162)
The factors (ALT grading and GGT grading) correlated with fatty liver or metabolic syndrome were evaluated using the multiple 
logistic regression analysis after adjustment for clinical and biochemical parameters. The several variables with P less than .1 in 
univariate analysis were included. 
* Adjusted for obesity, systolic blood pressure >130 mmHg, diastolic blood pressure >85 mmHg, metabolic syndrome, fasting blood 
sugar, GGT, 
† Adjusted for obesity, systolic blood pressure >130 mmHg, diastolic blood pressure >85 mmHg, metabolic syndrome, 
fasting blood sugar, ALT, 
§ Adjusted for age, sex, systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg, HDL 
cholesterol, fatty liver, body weight, GGT, 
∥ Adjusted for age, sex, systolic blood pressure >130 mmHg or diastolic blood pressure 
>85 mmHg, HDL cholesterol, fatty liver, body weight, ALT ALT grading (first 1-14 IU/L, second 15-19 IU/L, third 20-25 IU/L, 
and fourth 26-40 IU/L) GGT grading (first 1-10 IU/L, second 11-15 IU/L, third 16-24 IU/L, and fourth 25-50 IU/L).
Association of MS and fatty liver with ALT and
GGT activities
In male subjects, the presence of MS, its components, and 
the number of metabolic abnormalities increased with 
increased ALT grading, except the low HDL-C and fasting 
plasma glucose>100 mg/dL (Table 4). With increased ALT 
grading in female subjects, the presence of MS, its components, 
and the number of metabolic abnormalities increased, except 
the low HDL-C (Table 5). With increased GGT grading in 
total subjects, the presence of MS, its components, and the 
number of metabolic abnormalities increased, except the 
low HDL-C (Table 6). 
With increasing ALT grading, odds ratios for fatty liver 
elevated in third and fourth quartile in a dose dependent 
manner, after adjustment for obesity, systolic BP>130 mmHg, 
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although odds ratio in second quartile (0.81, 95% CI 0.47- 
1.39) has weaker risk than in first quartile. With increasing 
GGT grading, odds ratio for fatty liver elevated in third 
(1.04, 95% CI 0.48-2.23) and fourth quartile (1.29, 95% CI 
0.60-2.79) in a dose dependent manner, adjusted for obesity, 
systolic BP>130 mmHg, diastolic BP>85 mmHg, MS, fasting 
plasma glucose.
With increasing ALT grading, odds ratios for MS increased 
in a dose dependent manner from second quartile to fourth 
quartile. With increasing GGT grading, odds ratios for MS 
increased in third and fourth quartiles, although the risk for 
MS was weaker in second quartile than in first quartile 
(Table 7).
Levels of ALT and GGT activities within reference 
range to predict NAFLD and MS
In male subjects, when 21.5 IU/L of ALT activity was 
considered as cut-off level to predict NAFLD, sensitivity 
and specificity were 70.7% and 55.2%, respectively (area 
under curve 0.677, 95% CI 0.625-0.729, P<0.001). In female 
subjects, cut-off level of 16.95 IU/L in ALT activity had 
sensitivity of 69.2% and specificity of 56.5% to predict 
NAFLD (area under curve 0.662, 95% CI 0.602-0.723, P<0.001). 
In total subjects, when 19.5 IU/L in GGT activity was 
considered as cut-off level to predict NAFLD, sensitivity 
and specificity were 68.1% and 52.1%, respectively (area 
under curve 0.634, 95% CI 0.594-0.673, P<0.001).
To predict MS, in male subjects, 21.9 IU/L of ALT cut-off 
level had sensitivity of 66% and specificity of 48.9% (area 
under curve 0.629, 95% CI 0.553-0.705, P<0.001) and, in female 
subjects, 15.5 IU/L of ALT cut-off level had sensitivity of 
59.6% and specificity of 51.8% (area under curve 0.590, 
95% CI 0.528-0.652, P=0.004). In total subjects, 20.4 IU/L 
of GGT cut-off level had 68.8% of sensitivity and 53.0% of 
specificity to predict MS (area under curve 0.656, 95% CI 
0.602-0.710, P<0.001).
DISCUSSION
In the present study, both ALT and GGT activities, even within 
the reference interval, were correlated with incident NAFLD, 
even after adjusting for variable factors including presence of 
MS. Although the association of ALT activity with NAFLD was 
not significant in the second quartile, subjects in the fourth 
quartiles have risks for NAFLD to approximately three-fold than 
those in the lowest quartile. Although the association of GGT 
activity with NAFLD was weak, the odds ratio of GGT activity 
for NAFLD was elevated according to elevation of the GGT 
grading. In addition, ALT activity, within the reference interval, 
was associated with incident MS, even after adjustment for 
variable factors including fatty liver in a dose-dependent manner 
from second quartile. Although the association of GGT activity 
with MS was not significant in the second quartile and 95% CI 
include 1.0, subjects in the fourth quartiles have risks for MS to 
approximately two-fold than those in the lowest quartile in a 
dose dependent manner.
Among the hepatic enzymes, ALT is most closely related to 
liver fat accumulation.
24 Our results appear to agree with the 
findings of several previous studies that increased ALT 
concentration, even within the reference interval, is an inde-
pendent predictor of incident NAFLD
12 and ALT is more closely 
associated than GGT with both hepatic IR and a later decline in 
hepatic insulin sensitivity.
25 This finding could be explained by 
the higher specificity of ALT for liver injury.
24 Also, as a glu-
coneogenic enzyme,
12 increased ALT has been demonstrated 
to be an indicator of impaired insulin signaling, which 
might not necessarily be associated with liver injury due to 
hepatic steatosis.
26,27 GGT might also be involved in the patho-
genesis of NAFLD through another mechanism, such as oxidative 
stress.
28
Elevated ALT could be a prognostic marker for development 
of various MS-related diseases, including type 2 DM, cardio-
vascular disease, and atherothrombosis,
  and a minor ALT 
elevation is also an important feature for effective screening of 
MS.
7 Thus, individuals with a minor elevation in the serum ALT 
level that is close to the upper limits of the reference range are 
also of concern because elevated ALT itself is closely associated 
with IR, even in the absence of NAFLD and obesity.
7 Because 
the mean ALT activities in subjects with 2 or 3 metabolic risk 
factors is not particularly high, tending only to be close to the 
upper limit, screening for serum ALT levels may facilitate 
identifying the potential risk for MS-related diseases in the 
general population,
7 in addition to detection of liver disease, 
even within the reference interval.
The mechanism underlying the relationship between IR and 
GGT elevation has not been clarified, although hepatic steatosis 
or hepatic IR caused by visceral obesity may be the first 
mechanism.
29-33 Because oxidative stress can play a role in the 
pathophysiology of cardiovascular disease, and GGT has a 
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into most types of cells, oxidative stress provides a second 
possible mechanism.
34-36 Increased GGT activity may be a response 
to oxidative stress, one which can increase the transport of 
glutathione precursors into cells. In addition, GGT leaks into 
serum possibly as a result of normal cell turnover and cellular 
stress.
8 Subclinical inflammation may be another possible 
cause.
37,38 In the present study, the white blood cell counts were 
also related to serum GGT and ALT concentrations. The significant 
associations between serum GGT and ALT activities and MS, 
even after adjusting for fatty liver, suggest that another mechanism 
governs the relationship between serum enzymes and MS, such 
as oxidative stress or subclinical inflammation. 
In our study, the prevalence of NAFLD diagnosed by 
ultrasonography was 25.3%. Male gender was significantly 
associated with NAFLD. In addition, the increased ALT and 
GGT activities with the reference interval were associated 
with various cardiovascular disease risk factors, prevalence of 
fatty liver, number of components of metabolic abnormalities, 
and presence of MS. 
In this study, using ROC curve, cut-off levels of ALT and GGT 
activities to predict NAFLD or MS were estimated. In male 
subjects, ALT activities within third grading were considered to 
predict NAFLD and MS, as cut-off levels. In female subjects, 
ALT activities within second grading were estimated as adequate 
cut-off levels to predict NAFLD and MS. In total subjects, GGT 
activities within third grading were considered as cut-off levels 
to NAFLD and MS. Therefore, even ALT and GGT levels within 
reference range may be considered to predict NAFLD and/or 
MS. However, this study is inadequate to clarify significance of 
ALT and GGT activities within reference level as predictor of 
NAFLD and/or MS. 
In summary, even ALT and GGT activities within the 
reference interval correlated with incident NAFLD and MS in a 
dose-dependent manner, although the risks in lower quartiles 
were low according to the ALT or GGT grading. Therefore, 
increased ALT and GGT activities, despite remaining within the 
reference interval, might be an important preclinical marker of 
NAFLD and MS. Although the mechanism through which serum 
ALT and GGT are related to the risk for NAFLD and MS remains 
to be elucidated, ALT and GGT might be not only indicators of 
liver injury by hepatic steatosis, but also an early indicator of 
impaired insulin signaling, subclinical inflammation, and oxidative 
stress.
12 
Our study had some limitations. First, liver biopsies were not 
performed to determine hepatic steatosis and its severity. However, 
in other studies, ultrasonography was 82-94% sensitive and 66-95% 
specific in detecting fatty infiltration of the liver.
8 Second, other 
causes of liver disease, such as autoimmune hepatitis, hemo-
chromatosis, or Wilson’s disease, could not be ruled out. Third, 
enrolled numbers in each groups were different. Especially, 
enrolled numbers in group 1 were small. However, we suggest 
these differences may be attributed to prevalence according to 
the gradings rather than problem of study design. Also, because 
this study was performed in apparently healthy Korean people 
undergoing health check-ups at a hospital, the study had 
selection bias. A cross-sectional study, prospective, multi-center 
study should be performed to clarify the relationship between 
hepatic enzymes and metabolic risk. Lastly, influence of drug 
including herb was not considered in this study. 
In conclusion, grading of ALT and GGT activities with 
reference range correlated with NAFLD and MS, rather than the 
absolute normal limit. To date, although increased ALT and GGT 
concentrations are considered to have association with NAFLD 
and MS, it is unclear what underlies the relationship between 
enzymes and NAFLD and/or MS. Future studies are needed to 
demonstrate the related pathways and these correlation.
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